Rhythm Biosciences Limited
RHY.ASXHealth Care
Research, development and commercialisation of medical diagnostic technology
Market Data
$0.115
-0.0%$42.5M
-100000.0x
$-0.023
0.00%
-0.3%
Latest Earnings
Half-Year Financial Report and Appendix 4D
18 February 2026
Rhythm Biosciences reported a loss of $2.26M for the half-year, compared to a profit of $0.59M in the prior period, as the biotech company continues investing heavily in commercializing its ColoSTAT cancer diagnostic test and geneType genetic risk platform. The company successfully raised $3.75M in new capital and achieved key milestones including securing ISO laboratory accreditation for ColoSTAT and partnerships with NHS England and Memorial Sloan Kettering Cancer Center. Despite the current losses, the company is transitioning from development to commercialization with growing international presence. Key points: ColoSTAT achieved breakthrough clinical performance across colorectal cancer stages I-IV and secured ISO 15189:2022 laboratory accreditation for commercialization; NHS England selected ColoSTAT for independent evaluation, providing validation from one of world's most respected healthcare systems; Strategic partnerships secured including Memorial Sloan Kettering Cancer Center for geneType platform and distribution agreements in Australia and US
Recent Announcements
Half-Year Financial Report and Appendix 4D
Rhythm Biosciences reported a loss of $2.26M for the half-year, compared to a profit of $0.59M in the prior period, as the biotech company continues investing heavily in commercializing its ColoSTAT cancer diagnostic test and geneType genetic risk platform. The company successfully raised $3.75M in new capital and achieved key milestones including securing ISO laboratory accreditation for ColoSTAT and partnerships with NHS England and Memorial Sloan Kettering Cancer Center. Despite the current losses, the company is transitioning from development to commercialization with growing international presence. Key points: ColoSTAT achieved breakthrough clinical performance across colorectal cancer stages I-IV and secured ISO 15189:2022 laboratory accreditation for commercialization; NHS England selected ColoSTAT for independent evaluation, providing validation from one of world's most respected healthcare systems; Strategic partnerships secured including Memorial Sloan Kettering Cancer Center for geneType platform and distribution agreements in Australia and US
Get real-time alerts for RHY
Receive AI-powered earnings summaries and instant notifications when Rhythm Biosciences Limited releases results.
Register Free